Eli Lilly released the company’s first-quarter 2021 financial report and is abandoning plans to submit mirikizumab to health regulators for psoriasis.
Roche culled two more Phase II Covid-19 programs, as announced in the Swiss pharma giant’s first-quarter 2021 financial report.
Swiss drugmaker Roche predicted on April 21 that demand for the company’s drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests offset a pandemic-influenced slump in its main pharmaceuticals business.
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
Basel-based Lonza AG is moving to sell the company’s Lonza Specialty Ingredients division to private equity firms Bain Capital and Cinven for CHF 4.2 billion ($4.7 billion), completing a planned pivot to focus on Lonza Pharma, Biotech & Nutrition business.
U.S. biotech Amgen Inc. provided a 2021 earnings forecast below Wall Street estimates and said the company paused or halted enrollment for clinical trials of three cancer drugs.
Novavax Inc. is on track to begin a delayed U.S.-based, late-stage study of the company’s experimental coronavirus vaccine during November
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.
Shares of bluebird bio fell in trading after the company announced that the sickle cell disease gene therapy treatment bb1111 will not be submitted to the U.S. Food and Drug Administration for two more years.
